Geographic variation of mutagenic exposures in kidney cancer genomes

Sergey Senkin[1], Sarah Moody[2], Marcos Díaz-Gay[3,4,5], Behnoush Abedi-Ardekani[1], Thomas Cattiaux[1], Aida Ferreiro-Iglesias[1], Jingwei Wang[2], Stephen Fitzgerald[2], Mariya Kazachkova[3,6,5], Raviteja Vangara[3,4,5], Anh Phuong Le[2], Erik N. Bergstrom[3,4,5], Azhar Khandekar[3,4,5], Burçak Otlu[3,4,5,7], Saamin Cheema[2], Calli Latimer[2], Emily Thomas[2], Joshua Ronald Atkins[8], Karl Smith-Byrne[8], Ricardo Cortez Cardoso Penha[1], Christine Carreira[9], Priscilia Chopard[1], Valérie Gaborieau[1], Pekka Keski-Rahkonen[10], David Jones[2], Jon W. Teague[2], Sophie Ferlicot[11], Mojgan Asgari[12], Surasak Sangkhathat[13], Worapat Attawettayanon[14], Beata Świątkowska[15], Sonata Jarmalaite[16,17], Rasa Sabaliauskaite[16], Tatsuhiro Shibata[18,19], Akihiko Fukagawa[19,20], Dana Mates[21], Viorel Jinga[22], Stefan Rascu[22], Mirjana Mijuskovic[23], Slavisa Savic[24], Sasa Milosavljevic[25], John M.S. Bartlett[26], Monique Albert[27,28], Larry Phouthavongsy[28], Patricia Ashton-Prolla[29,30], Mariana R. Botton[31], Brasil Silva Neto[32,33], Stephania Martins Bezerra[34], Maria Paula Curado[35], Stênio de Cássio Zequi[36,37,38,39], Rui Manuel Reis[40,41], Eliney Faria[42], Nei Soares Menezes[43], Renata Spagnoli Ferrari[42], Rosamonde E. Banks[44], Naveen S. Vasudev[44], David Zaridze[45], Anush Mukeriya[45], Oxana Shangina[45], Vsevolod Matveev[46], Lenka Foretova[47], Marie Navratilova[47], Ivana Holcatova[48,49], Anna Hornakova[50], Vladimir Janout[51], Mark Purdue[52], Nathaniel Rothman[52], Stephen J. Chanock[52], Per Magne Ueland[53], Mattias Johansson[1], James McKay[1], Ghislaine Scelo[54], Estelle Chanudet[55], Laura Humphreys[2], Ana Carolina de Carvalho[1], Sandra Perdomo[1], Ludmil B. Alexandrov[3,4,5], Michael R. Stratton[2], Paul Brennan[1]*

[1]Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France, [2]Cancer, Ageing and Somatic Mutation, Wellcome Sanger Institute, Cambridge, UK, [3]Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, USA, [4]Department of Bioengineering, University of California San Diego, La Jolla, USA, [5]Moores Cancer Center, University of California San Diego, La Jolla,

USA, [6]Biomedical Sciences Graduate Program, University of California San Diego, La Jolla,

USA, [7]Department of Health Informatics, Graduate School of Informatics, Middle East

Technical University, Ankara, Turkey, [8]Cancer Epidemiology Unit, The Nuffield Department

of Population Health, University of Oxford, Oxford, UK, [9]Evidence Synthesis and

Classification Branch, International Agency for Research on Cancer (IARC/WHO), Lyon,

France, [10]Nutrition and Metabolism Branch, International Agency for Research on Cancer

(IARC/WHO), Lyon, France, [11]Service d'Anatomie Pathologique, Assistance Publique-

Hôpitaux de Paris, Univeristé Paris-Saclay, Le Kremlin-Bicêtre, France, [12]Oncopathology

Research Center, Iran University of Medical Sciences, Tehran, Iran, [13]Translational Medicine

Research Center, Faculty of Medicine, Prince of Songkla University, Hat Yai,

Thailand, [14]Department of Surgery, Urology, Faculty of Medicine, Prince of Songkla

University, Hat Yai, Thailand, [15]Department of Environmental Epidemiology, Nofer Institute of

Occupational Medicine, Łódź, Poland, [16]Laboratory of Genetic Diagnostic, National Cancer

Institute, Vilnius, Lithuania, [17]Department of Botany and Genetics, Institute of Biosciences,

Vilnius University, Vilnius, Lithuania, [18]Laboratory of Molecular Medicine, The Institute of

Medical Science, The University of Tokyo, Minato-ku, Japan, [19]Division of Cancer Genomics,

National Cancer Center Research Institute, Chuo-ku, Japan, [20]Department of Pathology,

Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan, [21]Occupational

Health and Toxicology, National Center for Environmental Risk Monitoring, National Institute

of Public Health, Bucharest, Romania, [22]Urology Department, "Carol Davila" University of

Medicine and Pharmacy - "Prof. Dr. Th. Burghele" Clinical Hospital, Bucharest,

Romania, [23]Clinic of Nefrology, Faculty of Medicine, Military Medical Academy, Belgrade,

Serbia, [24]Department of Urology, University Hospital "Dr D. Misovic" Clinical Center,

Belgrade, Serbia, [25]International Organization for Cancer Prevention and Research,

Belgrade, Serbia, [26]Cancer Research UK Edinburgh Centre, Institute of Genetics and

Cancer, University of Edinburgh, Edinburgh, Scotland, [27]Centre for Biodiversity Genomics,

University of Guelph, Guelph, Canada, [28]Ontario Tumour Bank, Ontario Institute for Cancer

Research, Toronto, Canada, [29]Experimental Research Center, Genomic Medicine

Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [30]Post-Graduate Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, [31]Diagnostic Laboratory Service, Personalized Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [32]Service of Urology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, [33]Post-Graduate Program in Medicine: Surgical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, [34]Department of Anatomic Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil, [35]Department of Epidemiology, A.C. Camargo Cancer Center, São Paulo, Brazil, [36]Department of Urology, A.C. Camargo Cancer Center, São Paulo, Brazil, [37]National Institute for Science and Technology in Oncogenomics and Therapeutic Innovation, A.C. Camargo Cancer Center, São Paulo, Brazil, [38]Latin American Renal Cancer Group – LARCG, São Paulo, Brazil, [39]Department of Surgery, Division of Urology, Sao Paulo Federal University - UNIFESP, São Paulo, Brazil, [40]Molecular Oncology Research Center, Barretos Cancer Hospital, Brazil, [41]Life and Health Sciences Research Institute (ICVS), School of Medicine, Minho University, Braga, Portugal, [42]Department of Urology, Barretos Cancer Hospital, Brazil, [43]Department of Pathology, Barretos Cancer Hospital, Brazil, [44]Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK, [45]Clinical Epidemiology, N.N.Blokhin National Medical Research Centre of Oncology, Moscow, Russia, [46]Department of Urology, N.N.Blokhin National Medical Research Centre of Oncology, Moscow, Russia, [47]Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, [48]Institute of Public Health & Preventive Medicine, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic, [49]Department of Oncology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic, [50]Institute of Hygiene & Epidemiology, 1nd Faculty of Medicine, Charles University, Prague, Czech Republic, [51]Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic, [52]Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA, [53]Bevital AS, Bergen, Norway, [54]Observational & Pragmatic Research

83   Institute Pte Ltd, Singapore, Singapore, [55]Department of Pathology, Radboud University

84   Medical Centre, Nijmegen, Netherlands

85   These authors contributed equally: Sergey Senkin, Sarah Moody

86   * Corresponding author: Paul Brennan

88   ABSTRACT

International differences in the incidence of many cancer types indicate the existence of

carcinogen exposures that have not been identified by conventional epidemiology yet

potentially make a substantial contribution to cancer burden[1]. This pertains to clear cell renal

cell carcinoma (ccRCC), for which obesity, hypertension, and tobacco smoking are risk factors

but do not explain its geographical variation in incidence[2]. Some carcinogens generate somatic

mutations and a complementary strategy for detecting past exposures is to sequence the

genomes of cancers from populations with different incidence rates and infer underlying

causes from differences in patterns of somatic mutations. Here, we sequenced 962 ccRCC

from 11 countries of varying incidence. Somatic mutation profiles differed between countries.

In Romania, Serbia and Thailand, mutational signatures likely caused by extracts of

Aristolochia plants were present in most cases and rare elsewhere. In Japan, a mutational

signature of unknown cause was found in >70% cases and <2% elsewhere. A further

mutational signature of unknown cause was ubiquitous but exhibited higher mutation loads in

countries with higher kidney cancer incidence rates (p-value $<6 \times 10^{-18}$). Known signatures of

tobacco smoking correlated with tobacco consumption, but no signature was associated with

obesity or hypertension suggesting non-mutagenic mechanisms of action underlying these risk

factors. The results indicate the existence of multiple, geographically variable, mutagenic

exposures potentially affecting 10s of millions of people and illustrate the opportunities for new

insights into cancer causation through large-scale global cancer genomics.

INTRODUCTION

The incidence rates of most adult cancers vary substantially between geographical regions and many such differences are unexplained by known risk factors[1]. Together with unexplained trends in incidence over time, this indicates the likely presence of unknown environmental or lifestyle causes for many cancer types[1]. Traditional epidemiological studies have identified many important lifestyle, environmental and infectious risk factors for cancer. However, they have had limited success in recent decades suggesting that alternative study designs are required if further risk factors are to be identified.

Characterization of mutational signatures within cancer genomes[3] is an approach complementary to conventional epidemiology for investigating unknown causes of cancer. Most cancers contain thousands of somatic mutations that have occurred over the lifetime of the individual. These can be caused by endogenous cellular processes, such as imperfect DNA replication and repair, or by exposure to exogenous environmental or lifestyle mutagens such as ultraviolet radiation in sunlight and compounds in cigarette smoke. Mutational signatures are the patterns of somatic mutation imprinted on genomes by individual mutational processes. Analysis of thousands of cancer genome sequences from most cancer types has established a set of reference mutational signatures including 71 single base substitution (SBS) or doublet base substitution (DBS) signatures, and 18 small insertion and deletion (ID) signatures[4]. A possible etiology has been suggested for 47 SBS/DBS signatures and nine ID signatures.

Kidney cancer has particularly high incidence rates in Central and Northern Europe, notably in the Czech Republic and Lithuania, and has shown increasing incidence in high income countries in recent decades (**Fig. 1**)[2]. Most kidney cancers are clear cell renal cell carcinomas (ccRCC)[3] for which obesity, hypertension and tobacco smoking are known risk factors[2]. However, these account for <50% of the global ccRCC burden and do not explain geographical or temporal incidence trends. Previous ccRCC genome sequencing studies have included

relatively modest numbers of individuals from a small number of countries with limited variation

in ccRCC incidence[5–9] and have not comprehensively examined associations between ccRCC

risk factors and mutational signatures. To detect the activity of unknown carcinogens involved

in ccRCC development and to investigate the mechanisms of action of known risk factors, we

generated and analyzed epidemiological and whole genome sequencing data from a large

international series of ccRCC[10].

RESULTS

A total of 962 ccRCC cases from 11 countries in four continents were studied, including Czech

Republic (*n*=259), Russia (*n*=216), United Kingdom (*n*=115), Brazil (*n*=96), Canada (*n*=73),

Serbia (*n*=69), Romania (*n*=64), Japan (*n*=36), Lithuania (*n*=16), Poland (*n*=13), and Thailand

(*n*=5; **Fig. 1**; **Table 1**; **Methods**). These encompass a broad range of ccRCC incidence, from

the highest global age-standardized rates (ASRs) of Lithuania and Czech Republic (ASRs of

14.5 and 14.4/100,000 respectively) to the relatively low rates of Brazil and Thailand (ASRs of

4.5 and 1.8/100,000 respectively)[11]. Epidemiological questionnaire data were available on sex,

age at diagnosis, and important risk factors including body mass index (BMI), hypertension,

and tobacco smoking (**Table 1, Supplementary Table 1**). DNAs from ccRCCs and blood from

the same individuals were extracted and whole genome sequenced to average coverage of

54-fold and 31-fold, respectively.

Somatic mutation burdens in the 962 ccRCC genomes ranged from 803 to 45,376 (median

5,093) for single base substitutions (SBS), 2 to 240 (median 53) for doublet base substitutions

(DBS), and 10 to 14,770 (median 695) for small insertions and deletions (**Supplementary**

Table 2). The average burden of all three mutation types differed between the 11 countries (p-

value $<2 \times 10^{-23}$, p-value $<2 \times 10^{-14}$, p-value $<6 \times 10^{-14}$, for SBSs, DBSs, and IDs, respectively).

In particular, the burden of all mutation types was elevated in Romania compared to other

countries (**Extended Data Fig. 1**). Principal Component Analysis (PCA) performed on the

proportions of the six primary SBS mutation classes (C>A, C>G, C>T, T>A, T>C, T>G) in each

sample identified a distinct cluster of mainly Romanian and Serbian cases and a further cluster

of mainly Japanese cases (**Extended Data Fig. 2**). The results, therefore, clearly demonstrate

geographical variation of somatic mutation loads and patterns in ccRCC.

To investigate the mutational processes contributing to the geographical variation in mutation

burdens we extracted mutational signatures and estimated the contribution of each signature

to each ccRCC genome (**Supplementary Tables 3-7**). Ten signatures with strong similarity to

a reference signature in the Catalogue of Somatic Mutations in Cancer (COSMIC) database

were extracted: SBS1, due to deamination of 5-methylcytosine[12]; SBS2 and SBS13, due to

cytosine deamination by Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like

(APOBEC) DNA editing enzymes[12]; SBS4, due to tobacco smoke mutagens[13]; SBS5, due to

an endogenous mutational process in which mutations accumulate with age[13]; SBS12, of

unknown cause; SBS18, due to DNA damage by reactive oxygen species[13]; SBS21 and

SBS44, due to defective DNA mismatch repair[13,14]; and SBS22, due to Aristolochic acid

exposure[15,16].

Five further SBS signatures were identified which were not well described by the COSMIC

catalogue (**Fig. 2**; **Supplementary Table 8**). SBS40a, SBS40b and SBS40c were present in

most ccRCC, accounting for, on average, ~30%, ~20%, and ~3% of mutations respectively

(**Fig. 2b**). Combined, they closely resemble the previously reported SBS40 (0.96 cosine

similarity), suggesting that the large number of ccRCC whole genomes analyzed here provides

the power to separate the constituent component signatures of SBS40. SBS40 was previously

reported frequently, and at high levels, in kidney cancer, but also in other cancers, and is of

unknown etiology. Like the composite SBS40, SBS40a is present in multiple cancer types.

However, SBS40b and SBS40c are largely restricted to ccRCC (**Supplementary Note,**

Extended Data Fig. 3). SBS_H was found in a single case and SBS_I is related to Aristolochic

acid exposure (see below; SBS_I has been renamed as SBS22b). Analysis of all other types

of mutational signatures, including doublet bases substitutions, small insertion and deletions,

copy number variants and structural variants, is presented in Supplementary results.

The mutation burdens of multiple SBS mutational signatures varied between the 11 countries.

SBS22 is thought to be caused by Aristolochic acids, mutagenic derivatives of plants of the

Aristolochia genus which are carcinogenic and also cause Balkan endemic nephropathy

(BEN), a kidney disease prevalent in areas adjacent to the Danube in Southeastern Europe[17].

SBS22 has previously been found in ccRCC, other urothelial tract cancers, and hepatocellular

carcinomas from Romania[5,18] and various countries in East and South-East Asia[15,16,19]. In this

study, SBS22 was present in high proportions of ccRCC from Romania (45/64, 70%), Serbia

(16/69, 23%), and Thailand (3/5, 60%), often with very high mutation burdens. Of note, given

the limited number of cases in Thailand, they may not be representative of ccRCC in that

region. The presence of SBS22 was strongly correlated with that of new signatures SBS_I,

DBS_D, and ID_C (**Extended Data Fig. 4-6**) which are, therefore, also probably due to

Aristolochic acid exposure. SBS_I, like SBS22, is composed predominantly of T>A mutations.

The signature identified previously as SBS22, has therefore been renamed SBS22a, and

SBS_I has been named SBS22b. The mutation burden of both SBS22a and SBS22b differed

between Serbia and Romania, with higher levels being detected in Romania, and away from

recognized BEN zones (**Fig 3a-c**). The two signatures may be due to different subsets of

Aristolochic acids, and/or to different metabolites, which induce slightly different mutational

patterns. Only five ccRCC cases were known to reside within recognized BEN zones,

suggesting no clear link between the two diseases. While the source of this exposure is

uncertain, these results indicate that a substantial proportion of the population over a wide

geographical area of Eastern Europe, possibly numbering in the 10s of millions, has been

exposed to Aristolochic acid containing compounds, the public health consequences of which

are uncertain.

SBS12 was present in 72% of Japanese and 2% of non-Japanese ccRCC (p-
value=4.7×10^{-78}) (**Extended Data Fig. 7h**). Compared to the mutation burdens imposed by
Aristolochic acid in ccRCC, SBS12 contributed modest mutation loads. SBS12 is composed
predominantly of T>C substitutions and exhibits strong transcriptional strand bias with more
T>C mutations on the transcribed than untranscribed strands of protein coding genes.
Transcriptional strand bias is typically caused by activity of transcription-coupled nucleotide
excision repair acting on bulky DNA adducts due to exogenous mutagenic exposures such as
tobacco smoke chemicals[13], ultraviolet light[13], Aristolochic acids[15], and aflatoxins[20]. Assuming
that transcription-coupled repair of DNA adducts is responsible for the SBS12 strand bias, the
adducts are likely on adenine. Alternatively, transcriptional strand bias can also be caused by
transcription-coupled damage[21,22]. The presence of SBS12 was replicated in two further series
of whole genome sequenced ccRCC from Japan including 14 cases from an independent
study group who undertook a broad genomic analysis of ccRCC but without detailed mutational
signature analysis[23], and a more recent unpublished series of 61 cases from an additional
cohort of ccRCC sequenced by the same center as the initial cohort (**Supplementary Note**).
SBS12 was present in 12/14 cases (85%) cases and 46/61 (75%) of cases, respectively.
SBS12 was previously reported in hepatocellular carcinomas[4,13] and additional analysis of
existing datasets revealed strong SBS12 enrichment in hepatocellular carcinomas from Japan
compared to other countries (p-value=3.8×10^{-15}; **Supplementary Note**). These results,
therefore, indicate that exposure to an agent contributing SBS12 mutations to kidney and liver
cancer is common in Japan and rare in the other 10 countries included in this study. The agent
responsible for SBS12 is unknown although the precedents provided by other mutational
signatures with strong transcriptional strand bias suggest that it is likely of exogenous
origin[21,22]. A polymorphism in aldehyde dehydrogenase 2 known to impair metabolism of
alcohol to aldehydes and common in Japan did not associate with levels of SBS12, and neither
did any other common germline variants (**Supplementary Note**).

SBS40a, SBS40b, and SBS40c were present in ccRCC from all 11 countries. The country-

specific average mutation burdens of SBS40a and SBS40b positively associated with country-

specific ASRs of kidney cancer incidence (p-value=0.0022 and p-value=5.1×10^{-18},

respectively; **Extended Data Fig. 8a**; **Fig. 4a, Supplementary Table 9**), with the highest

mutation loads in the Czech Republic and Lithuania. Kidney cancer incidence rates also vary

between the regions of the Czech Republic and SBS40b mutation burdens differed significantly

between these (p-value=0.011; **Fig 4b,c, Supplementary Table 10**), with the highest

attribution in the highest risk region. SBS40b exhibits modest transcriptional strand bias and,

assuming that transcription-coupled repair of DNA adducts is responsible, the adducts

underlying SBS40b are likely on pyrimidines. Insertion and deletion (indel) signatures ID5 and

ID8, which together contributed ~60% of the indel mutation burden on average, were also

strongly associated with country-specific kidney cancer ASR (p-value=1.3×10^{-10} and p-

value=7.1×10^{-5}, respectively, **Extended Data Fig. 8b,c**). Signatures ID5 and ID8 correlated

with each other (Spearman's r=0.78), as well as with SBS40b (r=0.79 and r=0.74, respectively)

indicating that they likely all constitute products of the same underlying mutational process.

Thus, the burdens of the full complement of mutation types generated by this mutational

process correlate with age-adjusted kidney cancer incidence rates. The overall mutational

burden did not, however, associate significantly with kidney cancer incidence rates (**Extended**

Data Fig. 9).

To investigate potential mutagenic agents underlying these geographically variable signatures,

an untargeted metabolomics screen of plasma was conducted on 901 individuals in the study,

from all countries except Japan (**Methods**). 2,392 metabolite features were obtained, including

944 independent peaks (r<0.85). Three features were associated with SBS4 (**Supplementary**

Table 11), with two identified as hydroxycotinine (p-value=2.9×10^{-9}) and cotinine (p-value=1.9

$\times 10^{-5}$), two major metabolites of nicotine[24]. Eight features were associated with SBS40b

(**Supplementary Table 11**). One feature was identified as N,N,N-trimethyl-L-alanyl-L-proline

betaine (TMAP; p-value=1.2×10^{-5}, **Supplementary Table 12**), increased levels of which

correlate strongly with reduced kidney function[25]. Other established measures of kidney

function, including cystatin C and creatinine, were correlated with TMAP (p-value = 2.5 x 10^{-30}

and 1.7 × 10^{-69}, respectively) and also showed evidence of positive association with SBS40b

(p-value=0.023 and 0.058, respectively). Thus, exposure to the mutagenic agent responsible

for SBS40b is associated with reduced kidney function. No recognized metabolome features

were significantly associated with any other signatures.

A total of 1962 "driver" mutations were found in 136 genes including *VHL*, *PBRM1*, *SETD2*

and *BAP1*, the known frequently mutated cancer genes in ccRCC (Methods) (**Fig. 5a,**

Supplementary Table 13)[9,26]. The frequencies of mutations in these genes were consistent

across countries (**Fig. 5b**). The spectrum of all driver mutations in ccRCC with Aristolochic

acid exposure (**Methods**) was enriched in T>A mutations compared to non-exposed cases

(25% vs 13%, p-value=0.0062, **Fig. 5c,d**) with similar enrichment specifically in VHL mutations

(30% vs 16%; **Fig. 5e,f**), and in the whole exomes (27% in exposed compared to 12% in

unexposed cases). Thus genome-wide Aristolochic acid mutagenesis has contributed in a

proportionate fashion to generation of driver mutations in Aristolochic acid-exposed ccRCC.

The driver mutation spectrum did not show statistically significant enrichment of T>C mutations

in SBS12 exposed cases (20% vs 12%, p = 0.069), but was consistent with the level of

enrichment in the exome (21% in exposed compared to 15% in unexposed cases). SBS40b

also did not show statistically significant enrichment possibly due to the ubiquitous exposure

and its relatively flat and featureless mutation profile.

Exogenous mutagenic exposures that ultimately cause cancer may be present during the early

stages of evolution of cancer clones. To time mutagenic exposures, the contribution of each

mutational signature to mutations in the primary clone (relatively early) and to mutations in

subclones (relatively late) were estimated[27,28] (**Methods**). All signatures of the putative

exogenous mutagenic exposures observed in ccRCC were present at relatively early stages

of cancer development, consistent with exposures to normal cells. SBS12, SBS22b, and

SBS40b showed higher activities in main clones compared to subclones (q-value=0.04, q-

value=0.02, q-value=2.3×10^{-5}, respectively) (**Extended Data Fig. 10**) and SBS22a showed

no significant difference[15,16]. By contrast, signatures due to endogenous mutational processes

including APOBEC DNA editing (SBS13) and oxidative damage (SBS18), were enriched in

subclones (q-value=1.6×10^{-4}, q-value=3.2×10^{-7}, respectively).

Established or suspected risk factors for ccRCC include age, tobacco smoking, obesity,

hypertension, diabetes, and environmental exposure to PFAS compounds[29]. Total SBS, DBS,

and ID mutation burdens associated with age, as did SBS1, SBS4, SBS5, SBS40a, SBS40b,

SBS22a, SBS22b, DBS2, ID1, ID5, and ID8. Total SBS (p-value=3.1×10^{-5}), DBS (p-

value=3.7×10^{-3}) and ID (p-value=1.3×10^{-4}) mutation burdens also associated with sex, with

males having higher mutation burdens than females, and with SBS40b showing a similar

association (p-value=9.3×10^{-5}). Associations with tobacco smoking were observed for SBS4

(p-value=5.3×10^{-6}) and DBS2 (p-value=2.4×10^{-7}), both known to be caused by tobacco

carcinogens[30,31]. These results suggest that the known increased risk of ccRCC with tobacco

smoking is due to direct exposure of the kidney to tobacco related mutagens (**Supplementary**

Note). Associations of particular mutational signatures with other ccRCC risk factors were not

observed (**Supplementary Tables 14, 15**). To complement this analysis of observational data,

associations between polygenic risk scores for known ccRCC risk factors and mutational

signatures[32,33] were examined (**Methods**). Consistent with the observational data, no

associations were found between genetically inferred risk factors and mutational signatures

except for tobacco smoking and DBS2 (p-value=0.01; **Supplementary Table 16**).

DISCUSSION

Somatic mutations in the genomes of 962 ccRCC patients from 11 countries indicate the

existence of multiple, widespread mutational processes exhibiting substantial geographical

variation in their contributions to ccRCC mutation loads. The results contrast with those from

552 esophageal squamous carcinomas from eight countries with widely different esophageal

carcinoma incidence rates in which geographical differences in mutation burdens or signatures

were not observed[34]. Together the studies implicate both geographically variable mutagenic

and non-mutagenic carcinogenic exposures contributing to global cancer incidence. Indeed,

the presence of mutational signatures associated with tobacco smoking but absence of

signatures associated with other known ccRCC risk factors, such as obesity and hypertension,

suggests that the latter may be mediated by non-mutagenic processes and, therefore, that

both classes of carcinogen contribute to the development of ccRCC.

The existence, identity, and carcinogenic effect of some of the agents underlying these

mutational processes are known. Aristolochic acids are believed to cause SBS22a/b, and its

associated signatures, but this study suggests that the geographical extent and proportion of

the population acquiring mutations in South-Eastern Europe is far greater than previously

anticipated, possibly affecting 10s of millions of individuals. The sources of the Aristolochic

acid exposure, the manner by which it is ingested and whether the exposure continues today

are uncertain, and further definition of the source and extent of this exposure is required in

order to provide a foundation for public health action.

The existence of the mutagenic exposures underlying SBS12 and SBS40b were not previously

suspected, and their causative agents are unknown. Based on current information, the

exposure causing SBS12 is restricted to Japan. However, larger studies are now indicated to

explore the geographical extent of exposure in Japan and neighboring countries, and the

proportions of their populations that have been exposed. Studies of Japanese migrants to other

countries are also likely to be informative regarding the potential source of exposure. In the

first instance this will be achievable by further sequencing of kidney and hepatocellular cancer

genomes. However, studies of normal tissues, using recently reported sequencing methods

allowing detection of somatic mutations in normal cells[35], and particularly relatively accessible

ones such as cells in urine that can be prospectively collected, may enable large population-

based studies providing better characterization of the exposure and its consequences. As with

exposure to Aristolochic acid in South-Eastern Europe, it is possible that 10s of millions of

individuals in East Asia are exposed to a potent mutagen, and identification of the source and

extent of exposure would seem to be a public health priority.

In contrast to Aristolochic acid and the agent causing SBS12, the exposure underlying SBS40b

appears to be globally ubiquitous. It predominantly causes mutations in ccRCC, with much

lower burdens in other cancer types, and generates mutation loads correlating strongly with

age and sex. There are few clues as to its origin or nature.

The incidence rates of ccRCC vary ~eightfold across the eleven countries from which ccRCCs

were sequenced. A strong positive correlation (p-value=5.5×10^{-18}) was found between the

average mutation loads attributable to SBS40b in each country (and also those of ID5 and ID8

which are correlated with SBS40b) and incidence of kidney cancer within each country. This

correlation reflects approximately a tripling of average country-specific SBS40b mutation loads

(a difference of ~1000 mutations) in parallel with the eightfold increase of country-specific ASR.

SBS40b mutation burdens also positively correlated with biomarkers of impaired kidney

function, reminiscent of the nephrotoxic effects of Aristolochic acids in Balkan endemic

nephropathy. It is possible that the increased SBS40b somatic mutation load itself engenders

this reduction in renal function. However, studies of other normal tissues suggest that they are

generally tolerant of elevated mutation burdens, except for manifesting a higher incidence of

neoplasia[36,37]. It is also possible that the agent underlying SBS40b is directly nephrotoxic, for

example by engendering DNA damage and a response to it, and that the mutations it

generates are immaterial to kidney function. It is also conceivable, however, that impaired renal

function, potentially due to many different causes, results in a metabolic state which itself

causes the elevated SBS40b mutation load. Whatever the mutational process underlying

SBS40b, it is plausible that it contributes to the geographical variation in the age standardized

rates of kidney cancer incidence rates. It is of public health interest to determine the cause of

SBS40b and, hence, to consider whether the exposure can be mitigated, potentially with

concomitant reduction in global ccRCC incidence rates.

The absence of any association between several known risk factors for ccRCC and mutation

burden, in particular for obesity and hypertension, supports a model of cancer development

where mutations are essential but additional factors affect the expansion of a mutated clone

and thus the chance of it progressing into cancer[38]. Further efforts at defining how lifestyle and

environmental exposures contribute to cancer development will therefore require a greater

understanding of both the causes of the mutations in cell clones in normal tissue, and the

further promotion of such mutant clones by non-mutagenic processes.

Finally, the substantial geographical variability of SBS12 and SBS22a/b, with most countries

not showing evidence of exposure, raises the possibility that additional mutational signature

studies of ccRCC involving more countries may reveal further mutagenic exposures.

Furthermore, the results relating to SBS40b highlight the prospect that a significant proportion

of global cancer burden may be caused by relatively ubiquitous exposures that are not readily

detectable by classical cancer epidemiology studies. The conduct of large scale whole genome

sequencing for other cancer sites across high and low risk populations around the world would

seem to be an appropriate strategy for detecting such novel cancer causing agents.

REFERENCES

1.   Brennan, P. & Davey-Smith, G. Identifying Novel Causes of Cancers to Enhance

Cancer Prevention: New Strategies Are Needed. *JNCI: Journal of the National Cancer*

Institute **114**, 353–360 (2022).

2.   Hsieh, J. J. *et al.* Renal cell carcinoma. *Nat Rev Dis Primers* **3**, 17009 (2017).

3.   Koh, G., Degasperi, A., Zou, X., Momen, S. & Nik-Zainal, S. Mutational signatures:

emerging concepts, caveats and clinical applications. *Nat Rev Cancer* **21**, 619–637

(2021).

4.   Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer.

Nature **578**, 94–101 (2020).

5.   Scelo, G. *et al.* Variation in genomic landscape of clear cell renal cell carcinoma

across Europe. *Nat Commun* **5**, 5135 (2014).

6.   Mitchell, T. J. *et al.* Timing the Landmark Events in the Evolution of Clear Cell Renal

Cell Cancer: TRACERx Renal. *Cell* **173**, 611-623.e17 (2018).

7.   Campbell, P. J. *et al.* Pan-cancer analysis of whole genomes. *Nature* **578**, 82–93

(2020).

8.   Degasperi, A. *et al.* A practical framework and online tool for mutational signature

analyses show intertissue variation and driver dependencies. *Nat Cancer* **1**, 249–263

(2020).

9.   The Cancer Genome Atlas Research Network. Comprehensive molecular

characterization of clear cell renal cell carcinoma. *Nature* **499**, 43–49 (2013).

10.   Mutographs Cancer Grand Challenge. *https://cancergrandchallenges.org/teams*.

11.   Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence

and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209–

249 (2021).

12.   Nik-Zainal, S. *et al.* Mutational Processes Molding the Genomes of 21 Breast

Cancers. *Cell* **149**, 979–993 (2012).

13.   Alexandrov, L. B. *et al.* Signatures of mutational processes in human cancer. *Nature*

500, 415–421 (2013).

14.   Drost, J. *et al.* Use of CRISPR-modified human stem cell organoids to study the origin

of mutational signatures in cancer. *Science (1979)* **358**, 234–238 (2017).

15.   Hoang, M. L. *et al.* Mutational Signature of Aristolochic Acid Exposure as Revealed by

Whole-Exome Sequencing. *Sci Transl Med* **5**, (2013).

16.   Poon, S. L. *et al.* Genome-wide mutational signatures of aristolochic acid and its

443   application as a screening tool. *Sci Transl Med* **5**, 197ra101 (2013).

444   17.   Grollman, A. P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic

445   disease. *Environ Mol Mutagen* **54**, 1–7 (2013).

446   18.   Turesky, R. J. *et al.* Aristolochic acid exposure in Romania and implications for renal

447   cell carcinoma. *Br J Cancer* **114**, 76–80 (2016).

448   19.   Wang, X.-M. *et al.* Integrative genomic study of Chinese clear cell renal cell carcinoma

449   reveals features associated with thrombus. *Nat Commun* **11**, 739 (2020).

450   20.   Huang, M. N. *et al.* Genome-scale mutational signatures of aflatoxin in cells, mice, and

451   human tumors. *Genome Res* **27**, 1475–1486 (2017).

452   21.   Haradhvala, N. J. *et al.* Mutational Strand Asymmetries in Cancer Genomes Reveal

453   Mechanisms of DNA Damage and Repair. *Cell* **164**, 538–549 (2016).

454   22.   Nik-Zainal, S. *et al.* The genome as a record of environmental exposure. *Mutagenesis*

455   gev073 (2015) doi:10.1093/mutage/gev073.

456   23.   Sato, Y. *et al.* Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat*

457   *Genet* **45**, 860–867 (2013).

458   24.   Dempsey, D. *et al.* Nicotine metabolite ratio as an index of cytochrome P450 2A6

459   metabolic activity. *Clin Pharmacol Ther* **76**, 64–72 (2004).

460   25.   Velenosi, T. J. *et al.* Untargeted metabolomics reveals N, N, N-trimethyl-L-alanyl-L-

461   proline betaine (TMAP) as a novel biomarker of kidney function. *Sci Rep* **9**, 6831

462   (2019).

463   26.   Sato, Y. *et al.* Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat*

464   *Genet* **45**, 860–867 (2013).

465   27.   Nik-Zainal, S. *et al.* The life history of 21 breast cancers. *Cell* **149**, 994–1007 (2012).

466   28.   Dentro, S. C., Wedge, D. C. & van Loo, P. Principles of Reconstructing the Subclonal

467   Architecture of Cancers. *Cold Spring Harb Perspect Med* **7**, (2017).

468   29.   Shearer, J. J. *et al.* Serum Concentrations of Per- and Polyfluoroalkyl Substances and

469   Risk of Renal Cell Carcinoma. *J Natl Cancer Inst* **113**, 580–587 (2021).

30. Nik-Zainal, S. *et al.* The genome as a record of environmental exposure. *Mutagenesis*

gev073 (2015) doi:10.1093/mutage/gev073.

31. Kucab, J. E. *et al.* A Compendium of Mutational Signatures of Environmental Agents.

Cell **177**, 821-836.e16 (2019).

32. Gabriel, A. A. G. *et al.* Genetic Analysis of Lung Cancer and the Germline Impact on

Somatic Mutation Burden. *JNCI: Journal of the National Cancer Institute* **114**, 1159–

1166 (2022).

33. Liu, Y., Gusev, A., Heng, Y. J., Alexandrov, L. B. & Kraft, P. Somatic mutational

profiles and germline polygenic risk scores in human cancer. *Genome Med* **14**, 14

(2022).

34. Moody, S. *et al.* Mutational signatures in esophageal squamous cell carcinoma from

eight countries with varying incidence. *Nat Genet* **53**, 1553–1563 (2021).

35. Abascal, F. *et al.* Somatic mutation landscapes at single-molecule resolution. *Nature*

593, 405–410 (2021).

36. Martincorena, I. *et al.* High burden and pervasive positive selection of somatic

mutations in normal human skin. *Science (1979)* **348**, 880–886 (2015).

37. Martincorena, I. *et al.* Somatic mutant clones colonize the human esophagus with age.

Science (1979) **362**, 911–917 (2018).

38. Fowler, J. C. & Jones, P. H. Somatic Mutation: What Shapes the Mutational

Landscape of Normal Epithelia? *Cancer Discov* **12**, 1642–1655 (2022).

FIGURE AND TABLE LEGENDS

Fig. 1: Eleven participating countries and estimated age-standardized incidence rates

of clear cell renal cell carcinomas.

Incidence of clear cell renal cell carcinomas (ccRCC), men and women combined, age-

standardized incidence rates (ASR) per 100,000, data from GLOBOCAN 2020. Markers

indicate countries included in this study (number of participating ccRCC patients per

country).

498

499   **Table 1. Summary of clear cell renal cell carcinomas risk factors included in this**

500   **study.**

501

502   **Fig. 2: Single base substitution signature operative in clear cell renal cell carcinomas.**

503   **(a)** TMB plot showing the frequency and mutations per Mb for each of the decomposed SBS

504   signatures. **(b)** Average relative attribution for single base substitution (SBS) signatures

505   across countries. Signatures contributing less than 5% on average are grouped in the

506   'Others' category, apart from SBS12 and AA-related signatures SBS22a and SBS22b. '<95%

507   confidence' category accounts for the proportion of mutation burden which could not be

508   assigned to any signature with confidence level of at least 95%. **(c)** Decomposed signatures,

509   including reference COSMIC signatures as well as *de novo* signatures not decomposed into

510   COSMIC reference signatures.

511

512   **Fig. 3: Geospatial analysis of Aristolochic acid-related SBS signatures.**

513   Distribution of Romanian and Serbian cases with known residential history, along with the

514   summed levels of SBS22a and SBS22b attributions (per-case and regional estimate), with

515   respect to the Balkan endemic nephropathy (BEN) areas. White circles represented cases

516   with no detected activity of SBS22a and SBS22b.

517

518   **Fig. 4: Association of SBS40b signature attribution with incidence of kidney cancer.**

519   **(a)** Number of mutations attributed to signature SBS40b against age-standardized incidence

520   rates (ASR) of kidney cancer in each of the eleven countries represented in the cohort. Error

521   bars represent standard errors of the mean. **(b)** Number of mutations attributed to signature

522   SBS40b in four regions of Czech Republic against ASR of kidney cancer in each region.

523   Error bars represent standard errors of the mean. In **(a)** and **(b)**, the p-values are shown for

524   the ASR variable in linear regressions across all cases, adjusted for sex and age of

525   diagnosis. **(c)** Levels of attribution of SBS40b signature within Czech Republic, with bar plots

showing the number of cases for each quartile of SBS40b attribution across Prague,

Olomouc, Ceske Budejovice, and Brno regions.

Fig. 5: Driver mutation analysis in clear cell renal cell carcinomas.

(a) Frequency of driver genes in the cohort. Only genes mutated in at least 10 cases are

shown. **(b)** Frequency of driver genes across countries. Thailand, Poland and Lithuania are

not shown due to low sample numbers. **(c)** SBS-96 mutational spectra of all driver mutations

in ccRCC for Aristolochic acid (AA)-exposed and unexposed cases. **(d)** Percentage of T>A

driver mutations in AA-exposed and unexposed cases. **(e)** SBS-96 mutational spectra of VHL

mutations in ccRCC for AA-exposed and unexposed cases. **(f)** Percentage of T>A VHL

mutations in AA-exposed and unexposed cases.

ONLINE METHODS

Recruitment of cases and informed consent

The International Agency for Research on Cancer (IARC/WHO) coordinated case recruitment through an international network of over 40 collaborators from the 11 participating countries (**Table1**; **Supplementary Table 17**). The inclusion criteria for patients were >=18 years of age (ranging from 23 to 87, with a mean of 60 and a standard deviation of 12), confirmed diagnosis of primary ccRCC and no prior cancer treatment. Informed consent was obtained for all participants. Patients were excluded if they had any condition that could interfere with their ability to provide informed consent or if there were no means of obtaining adequate tissues or associated data as per the protocol requirements. Ethical approvals were first obtained from each Local Research Ethics Committee and Federal Ethics Committee when applicable, as well as from the IARC Ethics Committee.

Bio-samples, data collection, and expert pathology review

Dedicated standard operating procedures, following guidelines from the International Cancer Genome Consortium (ICGC), were designed by IARC/WHO to select appropriate case series with complete biological samples and exposure information as described previously[1] (**Supplementary Table 17**). In brief, for all case series included, anthropometric measures were taken, together with relevant information regarding medical and familial history. Comparable smoking and alcohol history was available from all centers. Detailed epidemiological information on residential history was collected in Czech Republic, Romania, and Serbia. Potential limitations of using retrospective clinical data collected using different protocols from different populations were addressed by a central data harmonization to ensure a comparable group of exposure variables (**Supplementary Table 17**). All patient related data as well as clinical, demographical, lifestyle, pathological and outcome data were pseudonymized locally through the use a dedicated alpha-numerical identifier system before being transferred to IARC/WHO central database.

Original diagnostic pathology departments provided diagnostic histological details of

contributing cases through standard abstract forms. IARC/WHO centralized the entire

pathology workflow and coordinated a centralized digital pathology examination of the frozen

tumor tissues collected for the study as well as formalin-fixed, paraffin-embedded (FFPE)

sections when available, via a web-based report approach and dedicated expert panel

following standardized procedures as described previously[1]. A minimum of 50% viable tumor

cells was required for eligibility to whole genome sequencing.

In summary, frozen tumor tissues were first examined to confirm the morphological type and

the percentage of viable tumor cells. A random selection of tumor tissues was independently

evaluated by a second pathologist. Enrichment of tumor component was performed by

dissection of non-tumoral part, if necessary. 90 cases overlapped with a previously published

cohort recruited under the Cancer Genomics of the Kidney (CAGEKID) project[2], which were

also part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project[3].

DNA extraction

Extraction of DNA from fresh frozen tumor and matched blood samples was centrally

conducted at IARC/WHO except for Japan, which performed DNA extractions at the local

center following a similarly standardized DNA extraction procedure. Of the cases which

proceeded to the final analysis (n=962), germline DNA was extracted from either buffy-coat,

whole blood, or from adjacent normal tissue (*viz.*, samples from Japan) using previously

described protocols and methods[1].

Whole genome sequencing

In total, 1583 renal cell carcinoma cases were evaluated, with 1267 confirmed as ccRCC

cases. 116 (9%) were excluded due to insufficient viable tumor cells (pathology level), or

inadequate DNA (tumor or germline). DNA from 1151 cases was received at the Wellcome

Sanger Institute for whole genome sequencing. Fluidigm SNP genotyping with a custom panel

was performed to ensure that each pair of tumor and matched normal samples originated from

the same individual. Whole genome sequencing (150bp paired end) was performed on the

Illumina NovaSeq 6000 platform with target coverage of 40X for tumors and 20X for matched

normal tissues. All sequencing reads were aligned to the GRCh38 human reference genome

using Burrows-Wheeler-MEM (v0.7.16a and v0.7.17). Post-sequencing QC metrics were

applied for total coverage, evenness of coverage and contamination. Cases were excluded if

coverage was below 30X for tumor or 15X for normal tissue. For evenness of coverage, the

median over mean coverage (MoM) score was calculated. Tumors with MoM scores outside

the range of values determined by previous studies to be appropriate for whole genome

sequencing (0.92 – 1.09) were excluded. Conpair[4] (https://github.com/nygenome/Conpair)

was used to detect contamination, cases were excluded if the result was greater than 3%[5]. A

total of 962 cases passed all criteria and were included in subsequent analysis.

Somatic variant calling

Variant calling was performed using the standard Sanger bioinformatics analysis pipeline

(https://github.com/cancerit). Copy number profiles were determined first using the algorithms

ASCAT[6] and BATTENBERG[7], where tumor purity allowed. SNV were called with

cgpCaVEMan[8], indels were called with cgpPINDEL[9], and structural rearrangements were

called using BRASS. CaVEMan and BRASS were run using the copy number profile and purity

values determined from ASCAT where possible (complete pipeline, n=857). Where tumor

purity was insufficient to determine an accurate copy number profile (partial pipeline, n=105),

CaVEMan and BRASS were run using copy number defaults and an estimate of purity

obtained from ASCAT/BATTENBERG. For SNV additional filters (ASRD >= 140 and CLPM

==0) were applied to remove potential false positive calls. A second variant caller, Strelka2,

was run for SNVs and indels as consensus variant calling was previously shown to eliminate

algorithm specific artefacts and to generate highly reproducible mutational spectra compared

to using a single variant calling algorithm[1,10]. Only variants called by both the Sanger variant

calling pipeline and Strelka2 were included in subsequent analysis.

Validation of Japanese sequencing

The matched normal tissue sequenced was blood for all countries with the exception of Japan, where adjacent normal kidney was used. As Japan displayed an enrichment of SBS12, matched blood was obtained from 28 of the 36 patients to confirm that the source of the matched normal tissue was not influencing the result. In all cases, the mutational spectra of Japanese ccRCC generated using either blood or adjacent normal kidney matched each other with a cosine similarity of >0.99.

Generation of mutational matrices

Mutational matrices for single base substitutions (SBS), doublet base substitutions (DBS) and small insertions and deletions (ID) were generated using SigProfilerMatrixGenerator (https://github.com/AlexandrovLab/SigProfilerMatrixGenerator) with default options (v1.2.12)[11].

Mutational signature analysis

Mutational signatures were extracted using two algorithms, SigProfilerExtractor (https://github.com/AlexandrovLab/SigProfilerExtractor), based on nonnegative matrix factorization, and mSigHdp[12] (https://github.com/steverozen/mSigHdp), based on the Bayesian hierarchical Dirichlet process. For SigProfilerExtractor, *de novo* mutational signatures were extracted from each mutational matrix using SigProfilerExtractor with nndsvd_min initialization (NMF_init="nndsvd_min") and default parameters (v1.1.9)[13]. Briefly, SigProfilerExtractor deciphers mutational signatures by first performing Poisson resampling of the original matrix with additional renormalization (based on a generalized mixture model approach) of hypermutators to reduce their effect on the overall factorization[13]. Nonnegative matrix factorization (NMF) was performed using initialization with nonnegative singular value decomposition and by applying the multiplicative update algorithm using the Kullback–Leibler divergence as an objective function[13]. NMF was applied with factorizations between $k=1$ and $k=20$ signatures; each factorization was repeated 500 times[13]. *De novo* single base

substitution mutational signatures were extracted with SigProfilerExtractor for both SBS-288

and SBS-1536 contexts[11]. The results were largely concordant with the SBS-1536 *de novo*

signatures allowing additional separation of mutational processes, therefore the SBS-1536 *de*

novo signatures were taken forward for further analysis (**Supplementary Table 3**). Mutational

signatures for DBS and ID were extracted in DBS-78 and ID-83 contexts respectively

(**Supplementary Tables 4, 5**). Where possible, SigProfilerExtractor matched each *de novo*

extracted mutational signature to a set of previously identified COSMIC signatures[14], for SBS-

1536 signatures this requires collapsing the 1536 classification into the standard 96

substitution type classification with six mutation classes having single 3' and 5' sequence

contexts (**Supplementary Table 8**). This step makes it possible to distinguish between *de*

novo signatures which can be explained by a combination of the known catalog of mutational

process (which have not been completely separated during the extraction), and those which

have not been previously identified. mSigHdp extraction of SBS-96 and ID-83 signatures was

performed using the suggested parameters and using the country of origin to construct the

hierarchy. SigProfilerExtractor's decomposition module was subsequently used to match

mSigHdp *de novo* signatures to previously identified COSMIC signatures[14]. Further details on

the comparison of results between SigProfilerExtractor and mSigHdp and decomposition of *de*

novo signatures into COSMIC reference signatures can be found in the **Supplementary Note.**

Attribution of activities of mutational signatures

The *de novo* (SigProfiler) and COSMIC signature (SigProfiler and mSigHdp) activities were

attributed for each sample using the MSA signature attribution tool (v2.0,

https://gitlab.com/s.senkin/MSA)[15]. For COSMIC attributions, only COSMIC reference

signatures, which were identified in the decomposition of *de novo* signatures, were included in

the panel for attribution, in addition to *de novo* signatures which could not be decomposed into

COSMIC reference. At its core, the tool utilizes the nonnegative least squares (NNLS)

approach minimizing the L2 distance between the input sample and the one reconstructed

using available signatures. To limit false positive attributions, an automated optimization

procedure was applied by repeated removal of all signatures that do not increase the L2

similarity of a sample by >0.008 for SBS, >0.014 for DBS, and >0.03 for ID mutation types, as

suggested by simulations. These optimal penalties were derived using an optional parameter

(params.no_CI_for_penalties = false) utilizing a conservative approach in calculation of

penalties. Finally, a parametric bootstrap approach was applied to extract 95% confidence

intervals for each attributed mutational signature activity.

Driver mutations

A dNdS approach was used to identify genes under positive selection in ccRCC[16]. The analysis

was performed both for the whole genome (q-value<0.01), and with restricted hypothesis

testing (RHT) for a panel of 369 known cancer genes[16]. Variants in any gene identified as

under positive selection in global dNdS or in the 369-cancer gene panel were assessed as

potential drivers[16]. Candidate driver mutations were annotated with the mode of action using

the Cancer Gene Census (https://cancer.sanger.ac.uk/census) and the Cancer Genome

Interpreter tool (https://www.cancergenomeinterpreter.org). Missense mutations were

assessed using the MutationMapper tool (http://www.cbioportal.org/mutation_mapper).

Variants were considered likely drivers if they met any of the following criteria: *(i)* Truncating

mutations in genes annotated as tumor suppressors; *(ii)* mutations annotated as likely or

known oncogenic in MutationMapper; (iii) truncating variants in genes with selection (q-

value<0.05) for truncating mutations assumed to be tumor suppressors and thus likely drivers;

(iv) missense variants in all genes under positive selection and with dN/dS ratios for missense

mutations above 5 (assuming 4 of every 5 missense mutations are drivers) labelled as likely

drivers; or *(v)* in-frame indels in genes under significant positive selection for in-frame indels.

Evolutionary analysis

Subclonal architecture reconstruction was performed using the DPClust R package v2.2.8[7,17],

after obtaining cancer cell fraction (CCF) estimates by dpclust3p v1.0.8

(https://github.com/Wedge-lab/dpclust3p) based on the variant allele frequency provided by

the somatic variant callers and the copy number profiles determined by the BATTENBERG

algorithm. Only tumors with at least 40% purity according to BATTENBERG were considered

for further evolutionary analysis. For each tumor with at least one subclone, the respective

somatic mutations were split into clonal and subclonal mutations using the most probable

cluster assignment for each mutation as per the DPClust output. Mutations not assigned to a

cluster by DPClust were removed from further analysis. Clusters centered at a CCF>1.5 and

ones where chromosome X contributed the highest number of mutations were deemed

artifactual, and the respective mutations were removed. Samples with a total number of clonal

or subclonal mutations below 256 were also removed. Additionally, samples with poor

separation between the clonal and subclonal distributions (*e.g.*, subclone centered at a

CCF>0.80) were removed. Finally, only samples that had both a clone and at least one

subclone post-filtering were retained for further analysis. This yielded a total of 223 samples,

each with clonal and subclonal mutations. SigProfilerAssignment (v0.0.13)

(https://github.com/AlexandrovLab/SigProfilerAssignment) was used to identify the activity of

each mutational signature in each clone/subclone, and these activities were then normalized

by the total number of mutations belonging to the clone/subclone (*i.e.*, clonal mutations were

not included in the subclone). A two-sided Wilcoxon Signed-Rank Test[18] was used to assess

the differences in the relative activity of each mutational signature between the clones and

their respective subclones. P-values were corrected using the Benjamini-Hochberg

procedure[19] and reported as q-values in the manuscript.

Regressions

Signature attributions were dichotomized into presence and absence using confidence

intervals, with presence defined as both lower and upper limits being positive, and absence as

the lower limit being zero. If a signature was present in at least 75% of cases (SBS1, SBS40a,

SBS40b, ID1, and ID5), it was dichotomized into above and below the median of attributed

mutation counts. The binary attributions served as dependent variables in logistic regressions,

and relevant risk factors were used as factorized independent variables. To adjust for

confounding factors, sex, age of diagnosis, country, and tobacco status were added as

covariates in regressions. The Bonferroni method was used to test for significant p-values (*i.e.,*

a total of 224 comparisons for regressions with signatures, and a total of 24 comparisons for

regressions with mutation burden). P-values reported are raw (not corrected). Regressions

with incidence of renal cancer were performed as linear regressions with mutation burdens or

signature attributions (those present in at least 75% of cases) with confidence intervals not

consistent with zero as a dependent variable, and age-standardized rates (ASR) of renal

cancer obtained from Global Cancer Observatory (GLOBOCAN)[20], sex and age of diagnosis

as independent variables. ASR of renal cancer for regions of Czech Republic were obtained

from SVOD web portal[21]. Signatures present in less than 75% of cases were dichotomized into

presence and absence as previously mentioned and analyzed using the logistic regressions.

All regressions were performed on a sample basis.

Polygenic risk score (PRS) analysis of lifestyle risk factors

In this analysis, we used the genome-wide association studies (GWAS) summary statistics

estimated in European populations for well-established risk factors for ccRCC. For tobacco

smoking status, we used results from the GSCAN consortium meta-analysis of smoking

initiation (ever vs never status)[22]. For body mass index (BMI), the results of UK biobank (UKBB)

and GIANT consortium meta-analysis of continuous BMI were used[23]. GWAS summary

statistics related to hypertension, namely systolic blood pressure and diastolic blood pressure,

as well as the ones related to diabetes[24], such as fasting glucose and fasting insulin were also

obtained using UKBB studies[25].

Since all the GWAS summary statistics used in the current work were based on European

populations, we used ADMIXTURE tool (v1.3.0)[26] and principal component analysis (PCA) to

infer the unsupervised cluster of individuals with European genetic background within ccRCC

cases. Hapmap SNPs (n=1,176,821 variants) were extracted from the ccRCC whole-genome

sequence genotype data. After basic quality control using PLINK (v1.9b, www.cog-

genomics.org/plink/1.9/), 333 variants were removed due to missing genotype rate > 5%, 1,236

variants failed Hardy-Weinberg equilibrium test (p-values<10^{-8}), and 18,702 variants had

MAF<1% in our cohort. Additionally, 3 ambiguous variants and 21,358 variants within regions

of long-range, high linkage disequilibrium (LD) in the human genome (hg38) were excluded.

After pruning for linkage disequilibrium, 143,727 variants remained in ccRCC genotype data.

The 1000 genome reference population genotype data (phase 3) for Europeans (N=489),

Africans (YRI, N=108) and East Asians (N=103 from China and 104 from Japan)

(https://www.internationalgenome.org/data/) were filtered and merged with ccRCC genotype

data based on the pruned set of variants present in both datasets. ADMIXTURE was run on

the merged genotype data with k=3, which would correspond to the three ancestral continental

population groups that likely reflect the participants of our study. The ccRCC cases with

European genetic fraction greater than 80% by the ADMIXTURE analysis were selected for

the polygenic risk scores (PRS) analyses. To complement the ADMIXTURE analysis, PCA

was run on the same samples.

The initial genotype data based on whole-genome sequence from 849 ccRCC cases with

European genetic background consisted of biallelic SNPs with MAF >0.01% (to exclude ultra-

rare variants; N ~ 30 million variants). After basic quality control, variants with missing

genotype rate of greater than 5% (N=7,519,196 variants) with strong deviation from Hardy-

Weinberg equilibrium (p-values<10^{-8}, N=220,862) were excluded. For each GWAS trait, we

restricted our analyses to the biallelic SNPs with minor allele frequency (MAF) greater than 1%

in the 1000 genomes reference for European populations. For the selection of the independent

genome-wide significant hits (p-values<5×10^{-8}) of each GWAS summary statistic used to

generate the PRS, SNPs were clumped (r^2=0.1 within a LD window of 10 MB) using PLINK

(v1.9b, www.cog-genomics.org/plink/1.9/) based on the 1000 genomes European reference

population genotype data (N=489; ~ 10 million variants). Where a selected GWAS hit was not

found in ccRCC genotype data, we extracted proxies (r^2>0.8 in 1000 genomes) also present

in ccRCC dataset where possible (**Supplementary Table 18**). The variance of each genetic

trait explained by the genetic variants were calculated as previously suggested[27]. PRS was

subsequently calculated as the sum of the individual's beta-weighted genotypes using PRSice-

2 software[28]. Associations were estimated per standard deviation increase in the PRS, which

was normalized to have a mean of zero across ccRCC cases of European genetic ancestry.

Untargeted metabolomics association with signatures

Of the 962 subjects from the main analysis, 901 subjects were included in this sub-study – all

Japanese samples (n=36) as well as few cases from Czech Republic (n=13), Romania (n=5)

and Russia (n=3) were not included due to lack of available plasma samples. Samples were

randomized and analyzed as two independent analytical batches. Analysis was performed with

a UHPLC-QTOF-MS system that consisted of a 1,290 Binary LC and a 6,550 QTOF mass

spectrometer equipped with Jet Stream electrospray ionization source (Agilent Technologies),

using previously described methods[29]. Pre-processing was performed using Profinder

10.0.2.162 and Mass Profiler Professional B.14.9.1 software (Agilent Technologies). A "Batch

recursive feature extraction (small molecules)" process was employed for samples and blanks

to find $[M+H]^+$ ions. The two batches were processes separately and the resulting features

were aligned in Mass Profiler Professional. Chromatographic peak areas were used as a

measurement of intensity. No normalization or transformation of raw data was performed prior

to the downstream data analysis.

A total of 2,392 features were detectable in at least one of the 901 samples. Features present

in only one of the two batches were filtered out. Recursive filtering elimination was applied to

decrease redundancy from highly correlated variables ($r \geq 0.85$, Pearson's r calculated before

any transformation/imputation) by selecting the features with least missing data within clusters

of features. A total of 944 features were included in the statistical analysis. Features were pre-

processed: missing values were replaced with 1/5 of the minimal value of the feature before

applying mean centering and Pareto scaling. Each feature was regressed against both *de novo*

and COSMIC signatures, adjusting for sex and age of diagnosis, as well as body mass index

(BMI) and technical factors (batch, acquisition order) that could impact chromatographic peak

area. Models for SBS22a and SBS22b were restricted to Romanian and Serbian samples to

find potential pathways of Aristolochic acid exposure in the Balkan region. Logistic models

were used for zero-inflated signatures (≥30% zeros) while quasi-Poisson regressions were

used for the least zero-inflated signatures (SBS1, SBS40a, and SBS40b). To derive specific

false detection rates, random variables were created from permutations of the initial features

and regressed against signatures in the same fashion as true features. Maximum p-value

thresholds from regressions with random features were compared to adjusted p-value

thresholds according to Bonferroni's procedure. The more conservative approach was used in

selecting features of interest. Random forest models were also used as cross-checking

multivariate models to assess the relative importance of each feature in explaining the

signature attribution. As with univariate models, regression models were used for the least

zero-inflated signatures (<30% of zeros) while classification models were used for all other

signatures, with restriction to Romanian and Serbian samples for SBS22a and SBS22b.

Importance was estimated from the total decrease in node impurities from splitting on the

variable, averaged over all trees. Node impurity was measured by the Gini index for

classification, and by residual sum of squares for regression. The significance of importance

metrics for Random Forest models were estimated by permuting the response variable

(https://github.com/EricArcher/rfPermute).

Features considered for identification, along with their highly correlated counterparts, were

searched in Human Metabolome Database (HMDB), LipidMaps, Metlin, and Kegg. Compound

identity was confirmed by comparison of retention times and MS/MS fragmentation against

chemical standards when available, or otherwise against reference MS/MS spectra. Since the

feature 240.1468@0.8929933 was strongly correlated with several features identified as

TMAP (**Supplementary Table 11**), the integration of these features was inspected and

corrected manually, and regressed against SBS40b using the same model applied to features

selected for analysis. Creatinine was identified among the features by matching its retention

time and MS/MS spectra against a reference standard and also regressed against SBS40b in

the same fashion as other metabolites. Estimation of correlation between metabolic features

was done using linear regression adjusting for batch and acquisition order.

Targeted metabolomics analyses

Circulating levels of PFAS (Per- and Polyfluorinated Substances) and cystatin C compounds

were investigated using targeted mass spectrometry-based methods as described

previously[30,31].

Out of the 962 subjects from the main analysis, plasma samples from 909 subjects (from all

countries except Japan) were randomized and sent frozen in dry ice to each respective

laboratory for analyses. Measurement of cystatin C from 906 subjects included its native form

and isoforms (3Pro-OH cystatin C, cystatin C-desS, 3Pro-OH cystatin C-desS and cystatin C-

desSSP) that were modeled individually and for the total concentration of cystatin C isoforms.

Measurements of PFAS compounds included PFOA (Perfluorooctanoic Acid; total, branch,

linear), PFOS (Perfluorooctanoic Acid; total, branch, linear), PFHxS (Perfluorohexane

sulfonate), PFNA (Perfluorononanoic acid), PFDA (Perfluorodecanoic acid), MePFOSAA (n-

methylperfluoro-1 octanesulfonamido acetic acid), EtPFOSAA (2-(N-Ethyl-perfluorooctane.

sulfonamido) acetic acid).

Multivariable quasi-Poisson (for the least sparse signatures SBS1, SBS40a and SBS40b) and

logistic regression were used to estimate the association between plasma concentrations of

the aforementioned substances and mutational signatures. All compounds were modeled

continuously (log2-transformed) and categorically, with adjustments made by sex, age, date

of recruitment, country, BMI, tobacco and alcohol status in the case of PFAS molecules and

by sex, age and BMI, in the case of cystatin C.

Geospatial analyses

Geospatial analyses were performed to estimate the regional effect for signature attribution, particularly for signatures thought to be from exogenous exposure (SBS40b – unknown – and SBS22a/SB22b - Aristolochic acid). Residential history information was available for a large proportion of cases from the countries of interest: Czech Republic for SBS40b and Romania/Serbia for SBS22a/SBS22b. The 259 cases from Czech Republic within this study were recruited from 4 separate regions including Prague, České Budějovice (in Southern Bohemia), as well as Brno and Olomouc in the east of the country. Each individual residence was geocoded to its administrative region. All locations outside the country of recruitment were labeled as "Abroad". A multi-membership mixed model was used to account for the full list of regions in which each subject resided, as well as the proportion of life spent in that region before diagnosis. As dependent variable, signatures were inverse-normal transformed. Models were adjusted for sex and age of diagnosis (fixed effects). The regional effect was treated as random effect.

Data availability

Whole genome sequencing data and patient metadata are deposited in the European Genome-phenome Archive (EGA) associated with study EGAS00001003542. Aligned BAM files for all ccRCC cases included in the final analysis were deposited in dataset EGAD00001012102, variant calling files in dataset EGAD00001012222 and patient metadata in dataset EGAD00001012223. The metabolomics data are available upon request. All other data are provided in the accompanying **Supplementary Tables**.

Code availability

All algorithms used for data analysis are publicly available with repositories noted within the respective method sections and in the accompanying reporting summary. Code used for regression analysis and figures is available at:

https://gitlab.com/Mutographs/Mutographs_RCC.

Methods references

1.   Moody, S. *et al.* Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. *Nat Genet* **53**, 1553–1563 (2021).

2.   Scelo, G. *et al.* Variation in genomic landscape of clear cell renal cell carcinoma across Europe. *Nat Commun* **5**, 5135 (2014).

3.   Campbell, P. J. *et al.* Pan-cancer analysis of whole genomes. *Nature* **578**, 82–93 (2020).

4.   Whalley, J. P. *et al.* Framework for quality assessment of whole genome cancer sequences. *Nat Commun* **11**, 5040 (2020).

5.   Bergmann, E. A., Chen, B.-J., Arora, K., Vacic, V. & Zody, M. C. Conpair: concordance and contamination estimator for matched tumor–normal pairs. *Bioinformatics* **32**, 3196–3198 (2016).

6.   Van Loo, P. *et al.* Allele-specific copy number analysis of tumors. *Proceedings of the National Academy of Sciences* **107**, 16910–16915 (2010).

7.   Nik-Zainal, S. *et al.* The life history of 21 breast cancers. *Cell* **149**, 994–1007 (2012).

8.   Jones, D. *et al.* cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data. *Curr Protoc Bioinformatics* **56**, (2016).

9.   Raine, K. M. *et al.* cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events from Paired End Sequencing. *Curr Protoc Bioinformatics* **52**, (2015).

10.   Kim, S. *et al.* Strelka2: fast and accurate calling of germline and somatic variants. *Nat Methods* **15**, 591–594 (2018).

11.   Bergstrom, E. N. *et al.* SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events. *BMC Genomics* **20**, 685 (2019).

927   12.   Liu, M., Wu, Y., Jiang, N., Boot, A. & Rozen, S. G. mSigHdp: hierarchical Dirichlet

928   process mixture modeling for mutational signature discovery. *bioRxiv*

929   2022.01.31.478587 (2022) doi:10.1101/2022.01.31.478587.

930   13.   Islam, S. M. A. *et al.* Uncovering novel mutational signatures by de novo extraction

931   with SigProfilerExtractor. *Cell genomics* **2**, None (2022).

932   14.   Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer.

933   *Nature* **578**, 94–101 (2020).

934   15.   Senkin, S. MSA: reproducible mutational signature attribution with confidence based

935   on simulations. *BMC Bioinformatics* **22**, 540 (2021).

936   16.   Martincorena, I. *et al.* Universal Patterns of Selection in Cancer and Somatic Tissues.

937   *Cell* **171**, 1029-1041.e21 (2017).

938   17.   Dentro, S. C., Wedge, D. C. & van Loo, P. Principles of Reconstructing the Subclonal

939   Architecture of Cancers. *Cold Spring Harb Perspect Med* **7**, (2017).

940   18.   Wilcoxon, F. Individual Comparisons by Ranking Methods. *Biometrics Bulletin* **1**, 80

941   (1945).

942   19.   Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and

943   Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series*

944   *B (Methodological)* **57**, 289–300 (1995).

945   20.   Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence

946   and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* **71**, 209–

947   249 (2021).

948   21.   Dušek, L. *et al.* Epidemiology of Malignant Tumours in the Czech Republic

949   [online]. Masaryk University, Czech Republic, [2005]. *http://www.svod.cz/. Version 7.0*

950   *[2007], ISSN 1802 – 8861*.

951   22.   Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into

952   the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237–244 (2019).

953   23.   Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body

954   mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* **27**, 3641–

955   3649 (2018).

956   24.   Lagou, V. *et al.* Sex-dimorphic genetic effects and novel loci for fasting glucose and

957   insulin variability. *Nat Commun* **12**, 24 (2021).

958   25.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.

959   *Nature* **562**, 203–209 (2018).

960   26.   Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry

961   in unrelated individuals. *Genome Res* **19**, 1655–1664 (2009).

962   27.   Shim, H. *et al.* A Multivariate Genome-Wide Association Analysis of 10 LDL

963   Subfractions, and Their Response to Statin Treatment, in 1868 Caucasians. *PLoS*

964   *One* **10**, e0120758 (2015).

965   28.   Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-

966   scale data. *Gigascience* **8**, (2019).

967   29.   Loftfield, E. *et al.* Novel Biomarkers of Habitual Alcohol Intake and Associations With

968   Risk of Pancreatic and Liver Cancers and Liver Disease Mortality. *JNCI: Journal of the*

969   *National Cancer Institute* **113**, 1542–1550 (2021).

970   30.   Shearer, J. J. *et al.* Serum Concentrations of Per- and Polyfluoroalkyl Substances and

971   Risk of Renal Cell Carcinoma. *J Natl Cancer Inst* **113**, 580–587 (2021).

972   31.   Gao, J., Meyer, K., Borucki, K. & Ueland, P. M. Multiplex Immuno-MALDI-TOF MS for

973   Targeted Quantification of Protein Biomarkers and Their Proteoforms Related to

974   Inflammation and Renal Dysfunction. *Anal Chem* **90**, 3366–3373 (2018).

Acknowledgements

The authors would like to thank Laura O'Neill, Kirsty Roberts, Katie Smith, Maisie Farenden,

Siobhan Austin-Guest and the staff of DNA Pipelines at the Wellcome Sanger Institute for their

contribution. We are grateful for the support provided by Maja Milojevic, Christophe Lallemand,

Helene Renard, Aude Bardot, Andreea Spanu and Nivonirina Robinot as well as IARC General

Services, including the Laboratory Services and Biobank team led by Zisis Kozlakidis, the

Section of Support to Research overseen by Tamas Landesz and the Evidence Synthesis and

Classification Section led by Ian Cree, under IARC regular budget funding. The authors would

like to thank Gislaine Bergo, Riley Cox and Juliana Oliveira for help with data/sample

preparation and processing. The authors would also like to acknowledge the contributions of

the Leeds Biobanking and Sample Processing Lab, the Leeds Multidisciplinary RTB and the

Leeds NIHR BioRTB for provision of samples. The authors would like to thank Peter Campbell,

Inigo Martincorena, Tim Butler, Daniela Mariosa, Laura Torrens Fontanals, Wellington Oliveira

Dos Santos, Hana Zahed, Marc Gunter, Maggie Blanks and Mimi McCord for useful

discussions. The authors would also like to thank all the patients and their families involved in

this study.

Funding

This work was delivered as part of the Mutographs team supported by the Cancer Grand

Challenges partnership funded by Cancer Research UK (C98/A24032). This work was

supported by the Wellcome Trust grants 206194 and 220540/Z/20/A. The work was also partly

funded by Barretos Cancer Hospital, the Public Ministry of Labor of Campinas (Research,

Prevention, and Education of Occupational Cancer, 2015 to R.M.R.), and by Hospital de

Clínicas de Porto Alegre (180330 to P.A.-P., M.B., B.S.N.). The work was also partly supported

by the Practical Research Project for Innovative Cancer Control from the Japan Agency for

Medical Research and Development (AMED) (JP20ck0106547h0001 to T.S.), and by the

National Cancer Center Japan Research and Development Fund (2020-A-7 to A.F.). The work

was also partly funded by the 1st and 2nd Faculties of Medicine, Charles University, Prague

(CAGEKID to I.H.; Occupation, Environment and Kidney Cancer in Central and Eastern

Europe to A.H.). The work was also partly supported by the Ministry of Health of the Czech

Republic (MH CZ – DRO (MMCI, 00209805) to L.F. and M.N.). Measurement of PFAS

compounds was funded by Division of Cancer Epidemiology and Genetics of the National

Cancer Institute (USA). Measurement of cystatin C was funded by Cancer Research UK

(C18281/A29019).

1010

Contributions

The study was conceived, designed and supervised by M.R.S., P.B. and L.B.A. Analysis of

data was performed by S.Senkin, S.Moody, M.D.-G., T.C., A.F.-I., J.W., S.F., M.K., R.V.,

A.P.L., E.N.B., A.K., B.O., S.C., E.T., J.A., K.S.-B., R.C.C.P., V.G., D.J., J.W.T. and J.M.

Pathology review was carried out by B.A.-A., S.F. and M.A. Sample manipulation was carried

out by C.L., C.C. and P.C. Patient and sample recruitment was led or facilitated by

S.Sangkhathat, W.A., B.S., S.J., R.S., D.M., V.Jinga, S.R., S.Milosavljevic, M.M., S.Savic,

J.M.S.B, M.A., L.P., P.A.-P., M.B., B.S.N., S.M.B., M.P.C., S.C.Z., R.M.R., E.F., N.S.M.,

R.S.F., R.B., N.V., D.Z., A.M., O.S., V.M., L.F., M.N., I.H., A.H., V.Janout, S.C. and C.L., M.P.

P.K.-R., S.C., M.P., P.M.U. and M.J. contributed to data generation. Patient and sample

recruitment for Japanese cases was led by T.S. and A.F. Scientific project management was

carried out by L.H., E.C., G.S., A.C.D.C., A.F.-I. and S.P. S.Moody and S.Senkin jointly

contributed and were responsible for overall scientific coordination. The manuscript was

written by S.Senkin, S.Moody, M.R.S. and P.B. with contributions from all other authors.

1025

Competing interests

LBA is a compensated consultant and has equity interest in io9, LLC and Genome Insight. His

spouse is an employee of Biotheranostics, Inc. LBA is also an inventor of a US Patent

10,776,718 for source identification by non-negative matrix factorization. ENB and LBA declare

U.S. provisional applications with serial numbers: 63/289,601; 63/269,033; and 63/483,237.

LBA also declares U.S. provisional applications with serial numbers: 63/366,392; 63/367,846;

63/412,835; and 63/492,348. VM received honoraria from Ipsen, Bayer, AstraZeneca,

Janssen, Astellas Pharm and MSD, and provided expert testimony to BMS, Bayer, MSD and

Janssen. No other authors declare any competing interests.

1035

Disclaimer

Where authors are identified as personnel of the International Agency for Research on Cancer

/ World Health Organization, the authors alone are responsible for the views expressed in this

article and they do not necessarily represent the decisions, policy or views of the International

Agency for Research on Cancer / World Health Organization.

Corresponding author

Correspondence to Paul Brennan.

EXTENDED DATA FIGURE AND TABLE LEGENDS

Extended Data Fig. 1: Mutation burdens in clear cell renal cell carcinomas across countries.

Mutation burdens for single base substitutions (SBS) **(a)**, doublet base substitutions (DBS)

(b) and small insertions and deletions (ID) **(c)** show significant differences between countries

using the Kruskal-Wallis (two-sided) test (n=961 biologically independent samples). Four

SBS hypermutators and four ID hypermutators above mutation burden of 30000 and 3000,

respectively, were removed for clarity. Box and whiskers plots are in the style of Tukey. The

line within the box is plotted at the median while the upper and lower ends are indicated 25th

and 75th percentiles. Whiskers show 1.5*IQR (interquartile range) and values outside it are

shown as individual data points.

Extended Data Fig. 2: Principal component analysis of relative mutation counts.

PCA performed on relative mutation counts of all ccRCC tumors incorporating the six

mutation classes (C>A, C>G, C>T, T>A, T>C, T>G). Principal component 1 (PC1) clearly

separates the cluster of mostly Romanian cases that are enriched with AA signatures, often

at high mutation burdens. Principal component 3 (PC3) identifies a cluster of mostly

Japanese cases, enriched with signature SBS12.

Extended Data Fig 3: Attribution of signatures SBS40a, SBS40b, and SBS40c in a pan-

cancer cohort.

Attribution of signatures SBS40a, SBS40b, and SBS40c in a pan-cancer cohort, showing a

widespread distribution for SBS40a whilst SBS40b and SBS40c are only seen consistently in

clear cell renal cell carcinomas (ccRCC). The size of each dot represents the proportion of

samples of each tumor type where the signature is present. The color of each dot represents

the average mutation burden.

1071

Extended Data Fig. 4: Doublet-base substitution signatures operative in clear cell

renal cell carcinomas.

(a) Tumour mutation burden (TMB) plot showing the frequency and mutations per Mb for

each of the decomposed DBS signatures. **(b)** Average relative attribution for doublet-base

substitution (DBS) signatures across countries. Signatures contributing less than 5% on

average are grouped in the 'Other' category, apart from signature DBS_D. Category named

'<95% confidence' accounts for the proportion of mutation burden which could not be

assigned to any signature with confidence level of at least 95%. **(c)** Decomposed DBS

signatures, including reference COSMIC signatures as well as *de novo* signatures not

decomposed into COSMIC reference signatures.

1082

Extended Data Fig. 5: Small insertions and deletion signatures operative in clear cell

renal cell carcinomas.

(a) Tumour mutation burden (TMB) plot showing the frequency and mutations per Mb for

each of the decomposed ID signatures. **(b)** Average relative attribution for small insertion and

deletion (ID) signatures across countries. Signatures contributing less than 5% on average

are grouped in the 'Others' category, apart from signature ID_C. Category named '<95%

confidence' accounts for the proportion of mutation burden which could not be assigned to

any signature with confidence level of at least 95%. **(c)** Decomposed ID signatures, including

reference COSMIC signatures as well as *de novo* signatures not decomposed into COSMIC

reference signatures.

Extended Data Fig. 6: Correlation amongst signatures SBS22a, SBS22b, DBS_D, ID_C.

Extended Data Table 1: Presence of signatures SBS22a, SBS22b, DBS_D, ID_C across

countries.

Extended Data Fig. 7: Single base substitution signatures showing significant

differences in attributed mutation burden between countries.

Signatures SBS40a **(a)** and SBS40b **(b)** were more prevalent in high-incidence regions of

Czech Republic and Lithuania. Signatures SBS22a **(c)** and SBS22b **(d)** were enriched in

Romania and Serbia. SBS1 **(e)**, SBS5 **(f)** and SBS4 **(g)** showed moderate differences across

countries. Signature SBS12 **(h)** is highly prevalent in Japan. Five SBS1 hypermutators above

mutation burden of 1000 were removed for clarity. Box and whiskers plots are in the style of

Tukey. The line within the box is plotted at the median while the upper and lower ends are

indicated 25th and 75th percentiles. Whiskers show 1.5*IQR (interquartile range) and values

outside it are shown as individual data points.

Extended Data Fig. 8: Association of mutational signatures with incidence of renal

cancer.

Number of mutations attributed to signatures **(a)** SBS40a, **(b)** ID5 and **(c)** ID8 against age-

standardized incidence rate (ASR) of kidney cancer in each of the eleven countries

represented in the cohort. Error bars represent standard errors of the mean. The p-values

shown are for the ASR variable in linear regressions across all cases, adjusted for sex and

age of diagnosis.

1119   **Extended Data Fig. 9: Association of mutation burden with incidence of renal cancer.**

1120   Association of age-standardized rates (ASR) of kidney cancer incidence with SBS (**a**), DBS

1121   (**b**) and ID (**c**) mutation burdens across countries. Error bars represent standard errors of the

1122   mean. The p-values shown are for the ASR variable in linear regressions across all cases,

1123   adjusted for sex and age of diagnosis.

1124

Extended Data Fig. 10: Evolutionary analysis of mutational signatures in ccRCC.

Comparison of mutational signatures between clonal and subclonal mutations. Lines show

the change in relative activity between the clonal mutations (main) and subclonal mutations

(sub) within a sample. Blue and red lines represent an activity change of more than 6% (blue

indicates higher in the clonal mutations; red indicates higher in the subclonal mutations). Bar

plots show the distribution of activities in samples where the signature was present in the

clonal and/or subclonal mutations; this number is represented in the title of each plot as

X/223 for each signature. Black bars indicate one standard deviation away from the mean.

Significance was assessed using a two-sided Wilcoxon signed-rank test, and q-values were

generated using the Benjamini-Hochberg Procedure.

Fig.1

ASR (World) per 100 000

| 12.7–14.5 |
| 10.9–12.7 |
| 9.1–10.9 |
| 7.2–9.1 |
| 5.4–7.2 |
| 3.6–5.4 |
| 1.8–3.6 |
| 0.0–1.8 |

Not applicable
No data

Table 1

Country (ASR/100,000)		Brazil (4.5)	Canada (10.4)	Czechia (14.4)	Japan (7.6)	Lithuania (14.5)	Poland (8.1)	Romania (7.7)	Russia (10.3)	Serbia (7.4)	Thailand (1.8)	UK (10.3)	Total (4.6)
Number of cases		96	73	259	36	16	13	64	216	69	5	115	962
Sex	Female	44	22	93	8	9	5	25	98	30	4	42	380
	Male	52	51	166	28	7	8	39	118	39	1	73	582
Age at diagnosis (years)	0-45	15	6	27	3	1	2	6	43	16	0	6	125
	45-55	20	17	51	5	0	6	10	44	11	0	22	186
	55-65	30	17	77	8	9	1	20	91	27	2	41	323
	65-75	24	27	72	13	4	4	20	32	9	2	31	238
	75+	7	6	32	7	2	0	8	6	6	1	15	90
Year of recruitment	1999-2005			93			13	14	18				138
	2005-2010			111				19	70	1		31	232
	2010-2015		9	55	28			31	116	68		41	348
	2015-2020	96	64		8	16			12		5	43	244
Stage	I	28	3	123	24	6	0	33	94	32		53	396
	II	2	0	42	1	0	6	12	24	4		8	99
	III	16	23	46	6	5	5	18	65	26		38	248
	IV	7	10	38	5	2	2	1	33	7		16	121
	Missing	43	37	10		3					5		98
Body mass index	<20	3	2	5	2	0	2	2	9	8	0	6	39
	20-25	21	10	100	25	2	3	17	84	28	3	23	316
	25-30	35	24	85	7	6	6	30	40	20	1	45	299
	>30	37	37	69	2	8	2	14	83	13	1	41	307
	Missing							1					1
Hypertension	No	45	28	129	16	5	9	39	125	28	2	58	484
	Yes	51	44	130	20	10	4	24	91	41	3	56	474
	Missing			1		1		1				1	4
Diabetes	No	76	55	130	29	9		45	186	61	3	95	689
	Yes	20	16	36	7	7		4	12	8	2	20	132
	Missing		2	93			13	15	18				141
Family history of ccRCC	No	90	42	165	35	16		54	192	67	5	102	726
	Yes	5	4	22	1	0		1	6	2	0	3	43
	Missing	1	27	72			13	9	18			10	193
Tobacco status	Current smoker	23	21	66	9	4	6	11	52	18	1	28	239
	Ex-smoker	21	30	62	15	3	3	15	27	15	0	44	235
	Never	52	22	131	11	9	4	37	137	36	4	43	486
	Missing				1			1					2
PFOA (ng/mL)	Mean	0.7	1.6	3.4		1.3	5.4	1.3	1.5	1.3	2.2	3.3	2.2
	(st. dev.)	(0.5)	(1.1)	(2.1)		(0.6)	(4.1)	(0.9)	(1.4)	(0.6)	(2.2)	(1.7)	(1.9)

Fig. 2

a

b

c

Fig. 3

Fig. 4

Fig. 5

Extended Data Fig. 1.

a

b

c

Extended Data Fig. 2.

Extended Data Fig. 3.

Extended Data Fig. 4.

a

*Showing samples with counts more than 0

b

c

Extended Data Fig. 5.

a

*Showing samples with counts more than 0

b

c

Extended Data Fig. 6.

Extended Data Table 1.

Country	N cases	SBS22a (%)	SBS22b (%)	DBS_D (%)	ID_C (%)	SBS22a or SBS22b (%)	Any (%)
Romania	64	45 (70.3)	48 (75.0)	42 (65.6)	13 (20.3)	53 (82.8)	54 (84.4)
Serbia	69	16 (23.2)	33 (47.8)	11 (15.9)	3 (4.3)	35 (50.7)	36 (52.2)
Thailand	5	3 (60.0)	3 (60.0)	0 (0.0)	0 (0.0)	4 (80.0)	4 (80.0)
Brazil	96	3 (3.1)	3 (3.1)	1 (1.0)	0 (0.0)	3 (3.1)	3 (3.1)
Canada	73	2 (2.7)	0 (0.0)	2 (2.7)	1 (1.4)	2 (2.7)	3 (4.1)
Czechia	259	1 (0.4)	5 (1.9)	32 (12.4)	0 (0.0)	6 (2.3)	37 (14.3)
UK	115	1 (0.9)	0 (0.0)	31 (27.0)	0 (0.0)	1 (0.9)	31 (27.0)
Russia	216	0 (0.0)	1 (0.5)	26 (12.0)	0 (0.0)	1 (0.5)	27 (12.5)
Poland	13	0 (0.0)	0 (0.0)	1 (7.7)	0 (0.0)	0 (0.0)	1 (7.7)
Lithuania	16	0 (0.0)	1 (6.2)	1 (6.2)	0 (0.0)	1 (6.2)	2 (12.5)
Japan	36	0 (0.0)	1 (2.8)	1 (2.8)	0 (0.0)	1 (2.8)	1 (2.8)

Extended Data Fig. 7.

Extended Data Fig. 8.

a ASR/SBS40a association across countries

b ASR/ID5 association across countries

c ASR/ID8 association across countries

Extended Data Fig. 9.

a ASR/SBS burden association across countries

b ASR/DBS burden association across countries

c ASR/ID burden association across countries

Extended Data Fig. 10.